X39 patch's impact on circulating GHK and GHK-Cu levels investigated in healthy adults

GHK-Cu, a naturally occurring copper-binding peptide, is renowned for its pleiotropic effects on tissue regeneration, wound healing, and anti-aging processes. It plays a crucial role in promoting collagen and elastin synthesis, enhancing antioxidant defenses, and modulating inflammatory responses, making it a target for various therapeutic and cosmetic applications. Traditional delivery methods often involve injections or topical creams, which can have limitations in terms of systemic bioavailability, convenience, or localized irritation. The development of transdermal patch technology offers a non-invasive alternative for sustained release and systemic absorption. This study addresses the critical gap in understanding whether a transdermal patch, specifically the X39 patch, can effectively elevate circulating levels of GHK and GHK-Cu in healthy individuals, thereby potentially harnessing its regenerative benefits without the need for more invasive routes. The ability to reliably increase systemic GHK-Cu levels via a patch could revolutionize its accessibility and application in areas like skin health, connective tissue repair, and general longevity protocols.

This two-part clinical trial was designed to rigorously evaluate the impact of the X39 patch on systemic peptide levels. The study enrolled healthy adult participants, who were randomly assigned to either the active X39 patch group or a placebo patch control group. Participants were instructed to apply their assigned patch daily for a duration of 8 days. The primary objective was to quantify the change in circulating GHK and GHK-Cu blood levels from baseline (pre-intervention) to the end of the 8-day intervention period. Blood samples were collected at specified time points, and peptide concentrations were measured using validated blood assays. Researchers will compare the magnitude of change in GHK and GHK-Cu levels between the X39 patch group and the placebo group to determine the patch's efficacy in modulating these key biomarkers. Participants also completed a questionnaire to capture qualitative data, though the primary endpoints remain quantitative biochemical measures.

This research record describes the design and objectives of an ongoing clinical trial, rather than presenting completed results. Therefore, no specific findings regarding the efficacy of the X39 patch on circulating GHK and GHK-Cu levels are available at this stage. The study's primary aim is to determine if the X39 patch can significantly increase GHK and GHK-Cu concentrations in the bloodstream of healthy adults compared to a placebo. The investigators are specifically looking to quantify the change in these peptide levels from baseline to Day 8 in both intervention and control arms, and to assess the statistical difference between these changes. Once completed, the trial aims to provide definitive data on the patch's ability to modulate these key biomarkers, which are known for their roles in tissue repair, anti-inflammatory, and antioxidant processes.